INTRODUCTION: The routine use of positron emission tomography-computed tomography (PET-CT) in the staging of patients with esophageal carcinoma remains contentious, with conflicting reports of its benefit. In our unit, PET-CT has been used routinely in the staging of all patients considered for radical therapy (surgery or chemoradiotherapy). Our aim was to determine the frequency with which PET-CT influenced decision making in the management of patients with carcinoma of the esophagus or gastroesophageal junction. METHODS: CT, PET-CT, and outcome information were collected on 38 patients considered for radical therapy. Patient proformas, with and without PET-CT findings, were constructed and each independently reviewed in a randomized and blinded fashion by five multidisciplinary team members (three surgeons, two oncologists) and a treatment strategy determined. RESULTS:PET-CT changed the staging for ten patients (26%). This translated into a change in management decision for seven patients (18%). The concordance between individual management plans and treatment intent was 79% for CT (150 of 190 decisions) and it was 92% for PET-CT (175 of 190 decisions). Full concordance between multidisciplinary team members was 66% with CT staging and 74% with the addition of PET-CT. CONCLUSION: The use of PET-CT early in the staging algorithm for esophageal carcinoma altered the staging for a quarter of patients and the management for a fifth of patients, supporting its inclusion early in the staging algorithm.
RCT Entities:
INTRODUCTION: The routine use of positron emission tomography-computed tomography (PET-CT) in the staging of patients with esophageal carcinoma remains contentious, with conflicting reports of its benefit. In our unit, PET-CT has been used routinely in the staging of all patients considered for radical therapy (surgery or chemoradiotherapy). Our aim was to determine the frequency with which PET-CT influenced decision making in the management of patients with carcinoma of the esophagus or gastroesophageal junction. METHODS: CT, PET-CT, and outcome information were collected on 38 patients considered for radical therapy. Patient proformas, with and without PET-CT findings, were constructed and each independently reviewed in a randomized and blinded fashion by five multidisciplinary team members (three surgeons, two oncologists) and a treatment strategy determined. RESULTS: PET-CT changed the staging for ten patients (26%). This translated into a change in management decision for seven patients (18%). The concordance between individual management plans and treatment intent was 79% for CT (150 of 190 decisions) and it was 92% for PET-CT (175 of 190 decisions). Full concordance between multidisciplinary team members was 66% with CT staging and 74% with the addition of PET-CT. CONCLUSION: The use of PET-CT early in the staging algorithm for esophageal carcinoma altered the staging for a quarter of patients and the management for a fifth of patients, supporting its inclusion early in the staging algorithm.
Authors: P Flamen; A Lerut; E Van Cutsem; W De Wever; M Peeters; S Stroobants; P Dupont; G Bormans; M Hiele; P De Leyn; D Van Raemdonck; W Coosemans; N Ectors; K Haustermans; L Mortelmans Journal: J Clin Oncol Date: 2000-09-15 Impact factor: 44.544
Authors: Patrick B McDonough; David R Jones; K R Shen; Patrick G Northup; Roman L Galysh; Alfredo Hernandez; Grace E White; Michel Kahaleh; Vanessa M Shami Journal: Am J Gastroenterol Date: 2007-10-17 Impact factor: 10.864
Authors: Didier Lardinois; Walter Weder; Thomas F Hany; Ehab M Kamel; Stephan Korom; Burkhardt Seifert; Gustav K von Schulthess; Hans C Steinert Journal: N Engl J Med Date: 2003-06-19 Impact factor: 91.245
Authors: Richard G Berrisford; Wei-Lup Wong; David Day; Elizabeth Toy; Mark Napier; Keith Mitchell; Saj Wajed Journal: Eur J Cardiothorac Surg Date: 2008-03-06 Impact factor: 4.191
Authors: David M Bunting; Wesley W Lai; Richard G Berrisford; Tim J Wheatley; Brent Drake; Grant Sanders Journal: World J Surg Date: 2015-04 Impact factor: 3.352
Authors: Boris Sepesi; Daniel P Raymond; Marek Polomsky; Thomas J Watson; Virginia R Litle; Carolyn E Jones; Rui Hu; Xing Qiu; Jeffrey H Peters Journal: J Gastrointest Surg Date: 2009-10-01 Impact factor: 3.452
Authors: Omar S Al-Taan; Amar Eltweri; David Sharpe; Peter M Rodgers; Sukhbir S Ubhi; David J Bowrey Journal: World J Gastrointest Oncol Date: 2014-05-15
Authors: Chris Harrington; Lyn Smith; Jennifer Bisland; Elisabet López González; Neil Jamieson; Stuart Paterson; Adrian John Stanley Journal: World J Gastrointest Endosc Date: 2018-01-16